What Genes Affect Erectile Function? A Complete Genetic Guide

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

Erectile function is governed by at least four distinct biological systems, each with its own genetic variable layer. The standard clinical question — "what is causing this?" — typically investigates hormones (testosterone, prolactin, thyroid), vascular health (endothelial function, blood pressure, atherosclerosis), and psychological state. What it rarely investigates is the genetic architecture beneath all of these: the individual-specific genetic baseline that determines how efficiently each biological system operates, how sensitively each receptor responds to its signals, and why two men with identical testosterone levels and identical vascular health have such different erectile function. The PlexusDx Precision Peptide Genetic Test maps the genes that answer this question across 14 pathways, 49 peptides, and 150+ genetic insights, placing erectile function genetics within the complete 6-insight Sexual Health panel that describes the full biological picture.

Erectile Function Is a Multi-System Process — Each System Genetically Variable

Erection requires the coordinated output of four biological systems, each operating at its own genetic baseline:

System 1 — Central arousal: the brain-level signal that starts everything. Erection does not originate in the penis — it originates in the hypothalamus. Sexual stimuli generate neural and cognitive inputs that activate the melanocortin pathway in hypothalamic nuclei, particularly the PVN and MPOA. MC4R activation in these regions produces the descending parasympathetic signal that initiates penile smooth muscle relaxation. Without an adequate central arousal signal, the peripheral vascular cascade has no neural driver — regardless of testosterone levels, vascular health, or downstream pharmacological support.

System 2 — Vascular response: NO-driven smooth muscle relaxation. The central arousal signal activates both neuronal NOS (nNOS) in parasympathetic nerve terminals and endothelial NOS (eNOS, encoded by NOS3) in penile vascular endothelium. NO production → cGMP elevation → protein kinase G activation → smooth muscle relaxation → blood inflow → erection. NOS3 genotype determines how much NO the endothelium produces per unit of arousal signal — setting the vascular execution capacity of whatever central signal the brain has generated.

System 3 — Desire and motivation: the dopaminergic drive that sustains engagement. Erection in the context of sexual activity is sustained by ongoing desire and motivational engagement — the mesolimbic dopamine signal that maintains the neural arousal drive feeding the parasympathetic-vascular cascade. DRD2 receptor density (shaped by the Taq1A variant at rs1800497) determines how sensitively the reward system reads its own dopamine input, and therefore how robustly the motivational dimension of arousal is maintained through the sexual encounter.

System 4 — cGMP preservation and vascular persistence. cGMP — the smooth muscle relaxation second messenger generated by eNOS-derived NO — is degraded by PDE5. The duration and intensity of erection is partly governed by how rapidly PDE5 terminates the cGMP signal. PDE5 pathway support extends cGMP dwell time, amplifying whatever NO the eNOS system has produced. The upstream NOS3 genetic baseline determines how much cGMP is available for PDE5 pathway support to extend.

NOS3 (eNOS): The Primary Gene Affecting Erectile Function

Of all the genes affecting erectile function, NOS3 — encoding endothelial nitric oxide synthase — is the most directly mechanistically linked. Erection is fundamentally a nitric oxide-dependent event in corporal smooth muscle, and NOS3 genotype determines the baseline production capacity for that signal. Three functional NOS3 variants shape this baseline:

Glu298Asp (rs1799983): The T allele increases proteolytic cleavage of eNOS — reducing the amount of functional enzyme available to generate NO in penile endothelium. T/T homozygotes have significantly lower eNOS activity than G/G homozygotes in published platelet and endothelial assays. In erectile function terms, T/T men generate less NO from equivalent sexual stimulation — producing a weaker and shorter cGMP signal in corporal smooth muscle, and therefore less reliable smooth muscle relaxation and blood inflow at equivalent arousal intensity.

T-786C (rs2070744): The C allele reduces NOS3 promoter activity, producing less eNOS mRNA and protein from the outset — a transcriptional deficit that reduces the eNOS enzyme pool regardless of its per-enzyme activity. C/C homozygotes have lower basal eNOS expression, compounding any per-enzyme deficit from co-inherited Glu298Asp T alleles.

Intron 4 VNTR (4a/4b): The 4a allele reduces NOS3 mRNA levels by approximately 25–30% through intron-encoded microRNA regulation. Combined with T-786C C and Glu298Asp T alleles, the 4a/4a VNTR produces NOS3 impairment at the transcription, mRNA stability, and protein stability levels simultaneously — the most reduced eNOS genotype combination, with the most attenuated upstream NO signal for erectile function.

Full detail on NOS3 genetics and erectile function: eNOS (NOS3) and Nitric Oxide Genetics.

MC4R and the Melanocortin Pathway: Central Arousal Genetics

The second major gene category affecting erectile function is the melanocortin pathway — particularly MC4R. The central arousal signal that initiates the erectile vascular cascade runs through MC4R in the hypothalamic PVN and MPOA. MC4R activation by α-MSH produces the descending parasympathetic activation that drives both nNOS-dependent and eNOS-dependent NO production in penile vasculature.

MC4R genetic variants — including rs17782313 (near MC4R) and rare coding variants that reduce receptor expression or Gs coupling efficiency — attenuate this central arousal signal at its origin. Men with reduced-function MC4R variants may have adequate NOS3 activity, adequate testosterone, and adequate vascular health, yet still experience central arousal insufficiency — insufficient hypothalamic arousal drive to adequately activate the parasympathetic-vascular cascade that erection requires. This is the genetic basis of the clinical observation that some men do not respond adequately to PDE5 pathway support despite apparently intact peripheral vascular function: the limiting factor is upstream in the brain, not downstream in the vasculature.

Full detail on MC4R genetics and central arousal: The Melanocortin Pathway: Genetics of Central Sexual Response.

DRD2: Dopamine Receptor Genetics and the Motivational Dimension

Erectile function in real-world sexual contexts — as opposed to pharmacologically induced erection in clinical testing — depends on sustained motivational engagement. The mesolimbic dopamine system generates this motivational drive, and DRD2 receptor density shapes how robustly the system responds to sexual stimuli and sustains motivational arousal through the encounter.

The Taq1A variant (rs1800497) A1 allele is associated with approximately 30–40% lower striatal D2 receptor density. In erectile function terms, this means the motivational-dopaminergic dimension of sexual engagement is operating at a lower baseline gain — generating less compelling incentive salience from sexual stimuli, habituating faster in familiar sexual contexts, and producing more pronounced desire reduction under stress. These motivational factors directly influence the quality and sustainability of the central arousal signal that feeds the peripheral vascular erectile cascade — and are invisible to both testosterone measurements and vascular assessments.

The DRD2 × MC4R interaction is particularly significant: dopaminergic input to arcuate nucleus POMC neurons drives α-MSH production and release — making DRD2 receptor density a direct upstream driver of the melanocortin arousal signal. Low DRD2 → less α-MSH → less MC4R activation → less hypothalamic arousal → less parasympathetic drive → less erectile response, regardless of peripheral vascular NOS3 capacity.

Full detail: DRD2 Dopamine Receptor and Desire Pathways.

MTNR1B: Circadian Genetics and Erectile Function Timing

Nocturnal penile tumescence (NPT) — erections during REM sleep occurring approximately every 90 minutes through the night — is one of the most robust indicators of vascular and neurogenic erectile health. NPT depends on the circadian-coupled autonomic system that shifts toward parasympathetic dominance during the sleep phase: the same circadian architecture that MTNR1B governs through MT2 receptor-mediated synchronization of the reproductive axis and autonomic tone to the light-dark cycle.

MTNR1B variants that impair circadian precision affect erectile function in two ways:

Directly through NPT quality. MTNR1B-related circadian disruption reduces the depth and duration of REM sleep phases — compressing the parasympathetic-dominant windows during which NPT occurs. Reduced NPT frequency and rigidity is associated with reduced vascular conditioning of penile tissue (NPT is understood to serve a tissue-oxygenating function maintaining smooth muscle health) and with impaired overnight testosterone delivery to Leydig cells for morning testosterone synthesis.

Indirectly through testosterone rhythm attenuation. MTNR1B-governed circadian disruption flattens the testosterone diurnal rhythm — reducing the morning testosterone peak that provides androgenic priming for eNOS expression and function in penile endothelium. Men whose testosterone chronotype is disrupted by MTNR1B-related circadian asynchrony may have lower morning erectile readiness and more variable erectile response across the day than their total testosterone measurement suggests.

Full detail: MTNR1B and Circadian Sexual Function.

OXTR: Oxytocin Receptor Genetics and Vascular Arousal Facilitation

OXTR affects erectile function through a direct vascular mechanism: oxytocin released during sexual arousal activates OXTR expressed on vascular endothelium, stimulating eNOS phosphorylation at Ser1177 and increasing NO production independently of the neural arousal signal. This OXTR-mediated eNOS activation provides a supplementary NO production pathway during physical intimacy — most consequential in men with low-activity NOS3 genotypes, where the primary eNOS pathway produces less NO and OXTR-mediated supplementation represents a larger fraction of total available NO signal.

OXTR rs53576 G/G genotype (higher central oxytocin receptor sensitivity) is associated with more robust OXTR-mediated eNOS activation from equivalent oxytocin stimulation — and with more pronounced oxytocin release from physical affection and intimacy that initiates this vascular augmentation effect. A/A OXTR genotype produces attenuated oxytocin responsiveness and less OXTR-mediated eNOS activation.

Full detail: OXTR Oxytocin Receptor Genetics.

Adrenergic and Vasoactive Pathway Genetics

Beyond the primary Sexual Health pathway genes, several additional genetic variables shape erectile function through vasoactive mechanisms:

ADRA1A — alpha-1A adrenergic receptor variants that increase penile smooth muscle vasoconstrictor tone raise the threshold that NO-mediated vasodilation must overcome to produce erection. High alpha-adrenergic tone opposes the vasodilatory cascade from both the eNOS and prostaglandin sides of the vasoactive system.

PTGIS / PTGER — prostaglandin synthesis and receptor variants that reduce the prostaglandin pathway's contribution to cAMP-mediated smooth muscle relaxation limit the parallel vasodilatory route that supplements NOS3-dependent NO signaling. Men with reduced PTGIS or PTGER function have less prostaglandin pathway backup when the NO pathway is genetically constrained.

ROCK1/ROCK2 — Rho-kinase variants increasing calcium-sensitization-mediated contractile tone in corporal smooth muscle require stronger vasodilatory input to achieve equivalent smooth muscle relaxation — raising the total vasodilatory threshold for erection across all three vasoactive systems.

Full vasoactive pathway detail: Vasoactive Pathway Genetics for Sexual Health.

How the Genes Work Together

The genes affecting erectile function don't operate independently — they form a connected cascade. Understanding the interaction is as important as knowing each gene individually:

DRD2 → MC4R: Low DRD2 receptor density reduces dopaminergic α-MSH drive, attenuating the MC4R arousal signal before it even reaches the hypothalamus. Both must be functional to generate adequate central arousal.

MC4R → NOS3: Central arousal signal quality determines how much neural nNOS activation reaches the corporal vasculature — and therefore how much of the eNOS NO production is supplemented by neural-origin NO. Low MC4R activity compounds low-activity NOS3 genotype at the vascular execution level.

NOS3 × MTHFR: MTHFR C677T impairment reduces BH4 availability for eNOS coupling — converting even adequate NOS3 genotype into functionally lower NO output through eNOS uncoupling. A cross-pathway variable that constrains erectile vascular function from outside the Sexual Health pathway.

OXTR × NOS3: OXTR-mediated eNOS activation supplements the primary eNOS pathway during intimate physical contexts — most consequential for NOS3 low-activity genotypes where supplementary NO sources carry disproportionate weight in the total vascular arousal response.

The complete picture of how all six Sexual Health insights interconnect for erectile function is in the Complete Guide to Genetic Sexual Health Testing.

The Precision Peptide Genetic Test analyzes how your genes influence sexual health and related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to map the genetic architecture shaping your erectile function? Take the Precision Peptide Genetic Test

Frequently Asked Questions About Genes and Erectile Function

What is the most important gene for erectile function?

NOS3 is the most directly mechanistically linked — encoding eNOS, which produces the nitric oxide that drives corporal smooth muscle relaxation. MC4R governs the central arousal signal activating eNOS, DRD2 governs motivational desire, and MTNR1B governs circadian NPT quality. The Precision Peptide Genetic Test analyzes all six within 14 pathways and 150+ insights.

Can genetics cause erectile dysfunction?

Genetics can create biological predispositions that increase susceptibility — low-activity NOS3 reducing eNOS NO production, reduced-function MC4R attenuating central arousal, and DRD2 A1 allele reducing motivational desire. These are tendencies, not diagnoses. Erectile dysfunction is multifactorial. Results should always be interpreted with a qualified healthcare provider.

Why doesn't my testosterone level explain my erectile function?

Testosterone sets the androgenic environment eNOS expression and sexual motivation depend on — but NOS3 genetics determines eNOS activity, MC4R genetics determines central arousal quality, DRD2 genetics determines motivational desire drive, and MTNR1B genetics determines circadian NPT. The Precision Peptide Genetic Test maps these as 6 Sexual Health insights within 14 pathways, 150+ insights.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education